Reciprocal REGγ-mTORC1 regulation promotes glycolytic metabolism in hepatocellular carcinoma

Liangfang Yao,Yang Xuan,Haiyang Zhang,Bo Yang,Xinglong Ma,Tianzhen Wang,Tianyuan Meng,Wenshe Sun,Haibin Wei,Xueqing Ma,Robb Moses,Jianru Xiao,Pei Zhang,Chao Ge,Jinjun Li,Lei Li,Xiaotao Li,Jinbao Li,Bianhong Zhang

DOI: https://doi.org/10.1038/s41388-020-01558-8

IF: 8.756

2020-11-23

Oncogene

Abstract:Despite significant progression in the study of hepatocellular carcinoma (HCC), the role of the proteasome in regulating cross talk between mTOR signaling and glycolysis in liver cancer progression is not fully understood. Here, we demonstrate that deficiency of REGγ, a proteasome activator, in mice significantly attenuates DEN-induced liver tumor formation. Ablation of REGγ increases the stability of PP2Ac (protein phosphatase 2 catalytic subunit) in vitro and in vivo, which dephosphorylates PRAS40 (AKT1 substrate 1) and stabilizes the interaction between PRAS40 and Raptor to inactive mTORC1-mediated hyper-glycolytic metabolism. In the DEN-induced animal model and clinical hepato-carcinoma samples, high levels of REGγ in HCC tumor regions contribute to reduced expression of PP2Ac, leading to accumulation of phosphorylated PRAS40 and mTORC1-mediated activation of HIF1α. Interestingly, mTORC1 enhances REGγ activity in HCC, forming a positive feedback regulatory loop. In conclusion, our study identifies REGγ-PP2Ac-PRAS40 axis as a new layer in regulating mTORC1 activity and downstream glycolytic alterations during HCC development, highlighting the REGγ-proteasome as a potential target for personalized HCC therapy.

oncology,genetics & heredity,biochemistry & molecular biology,cell biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to understand how REG γ (a proteasome activator) promotes glycolytic metabolism and tumor growth by regulating the mTORC1 signaling pathway in hepatocellular carcinoma (HCC). Specifically, the study aims to reveal the mutual positive regulatory mechanism between REG γ and mTORC1, and how this mechanism affects the glycolytic process and tumor development in liver cancer cells. In addition, the study also explores the new role of the REG γ - PP2Ac - PRAS40 axis in regulating mTORC1 activity and downstream glycolytic changes, emphasizing the importance of REG γ - proteasome as a potential target for personalized HCC treatment.

The main findings of the paper include:
1. **REG γ promotes DEN - induced HCC in mice**: By comparing REG γ+/+ and REG γ−/− mice, the study found that REG γ deficiency significantly delayed the development of DEN - induced liver tumors, reducing the number and size of tumors.
2. **REG γ promotes glycolytic gene expression through the mTORC1 - HIF - 1α pathway**: The study shows that REG γ promotes the expression of glycolysis - related genes by enhancing the activity of mTORC1 and then up - regulating the expression of HIF - 1α.
3. **REG γ inhibits the phosphorylation of PRAS40 by promoting the degradation of PP2Ac**: REG γ can accelerate the degradation of PP2Ac, leading to the dephosphorylation of PRAS40, and then inhibiting the activity of mTORC1.
4. **There is a positive - feedback regulation between REG γ and mTORC1**: The activation of mTORC1 can promote the expression of REG γ, and the increase of REG γ further enhances the activity of mTORC1, forming a positive - feedback loop.

These findings not only reveal the important role of REG γ in hepatocellular carcinoma, but also provide new ideas for the development of personalized treatment methods for HCC.